SCHEMBL5849340

SCHEMBL5849340

COc1ccc(Oc2cncc(C=C[C@@H]3CCCN3)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 4/20 0.45
ROCK2 O75116 2/20 0.43
MAP4K4 O95819 2/20 0.43
PRKACA P17612 2/20 0.43
ROCK1 Q13464 2/20 0.43
DYRK1A Q13627 2/20 0.43
PKN2 Q16513 2/20 0.43
CLK4 Q9HAZ1 2/20 0.43
NTRK3 Q16288 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
STK17A Q9UEE5 1/20 0.43
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
CHRNB2 P17787 4/20 0.38
CHRNB4 P30926 3/20 0.38
CHRNA3 P32297 3/20 0.38
CHRNA4 P43681 2/20 0.38
CHRNA7 P36544 1/20 0.38
KHK P50053 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5850636 1.00 AKT1 (0.45) AKT1ROCK2MAP4K4PRKACAROCK1
SCHEMBL5849329 1.00 AKT1 (0.45) AKT1ROCK2MAP4K4PRKACAROCK1
SCHEMBL5850489 0.88 AKT1 (0.45) AKT1ROCK2MAP4K4PRKACAROCK1
SCHEMBL5848605 0.88 AKT1 (0.45) AKT1ROCK2MAP4K4PRKACAROCK1
SCHEMBL5848620 0.88 AKT1 (0.45) AKT1ROCK2MAP4K4PRKACAROCK1
SCHEMBL5848897 0.85 AKT1 (0.47) AKT1ROCK2MAP4K4PRKACAROCK1
SCHEMBL5849085 0.85 AKT1 (0.47) AKT1ROCK2MAP4K4PRKACAROCK1
SCHEMBL5848903 0.85 AKT1 (0.47) AKT1ROCK2MAP4K4PRKACAROCK1
SCHEMBL5849672 0.81 CHRNB2 (0.46) AKT1ROCK2MAP4K4PRKACAROCK1
SCHEMBL5849015 0.81 CHRNB2 (0.46) AKT1ROCK2MAP4K4PRKACAROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7101896-B2 Pharmaceutical compositions and methods for use TARGACEPT, INC. (US) 2006-09-05 US disclosed
US-20050267111-A1 Pharmaceutical compositions and methods for use DULL GARY M 2005-12-01 US disclosed
US-6890935-B2 Pharmaceutical compositions and methods for use TARGACEPT, INC. (US) 2005-05-10 US disclosed
US-20020058652-A1 Pharmaceutical compositions and methods for use TARGACEPT, INC. 2002-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267111-A1 Pharmaceutical compositions and methods for use CYP3A7, AADAC, CYP2B6 AKT1 3325/4885ROCK2 3444/4885MAP4K4 3385/4885
US-20020058652-A1 Pharmaceutical compositions and methods for use CYP3A7, AADAC, CYP2B6 AKT1 3325/4885ROCK2 3444/4885MAP4K4 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.